Well I suspect that there will be a CR in the not too distant future. Let's not forget that this is a fledging medical tech and the costs of trials, marketing, distribution and the like are a financial burden for any business. The difference is that now, following the stellar news yesterday, is that this product has been validated. We know this boat will float and that has de-risked the stock massively. The rest will take care of itself.
Ann: Neurotech Presentations, page-5
-
- There are more pages in this discussion • 102 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
